Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib monotherapy versus axitinib + lomustine in recurrent glioblastoma
2011-000900-16Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Mar 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Axitinib monotherapy with Axitinib + lomustine (2 arms). Primary endpoint: 6-month progression-free survival rate. Started Mar 2011; status: completed.
02
Drugs
axitiniblomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2011-000900-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000900-16.